TEVA PHARMACEUTICAL INDUSTRIES Reports Third Quarter Earnings Results for FY2023
November 20, 2023
🌥️Earnings Overview
On November 8, 2023 TEVA PHARMACEUTICAL INDUSTRIES ($NYSE:TEVA) announced its financial results for Q3 of FY 2023, ending September 30, 2023. The company posted a 7.1% YOY increase in total revenue to USD 3850.0 million and a 42.9% year-over-year increase in net income to USD 80.0 million.
Market Price
On Wednesday, TEVA PHARMACEUTICAL INDUSTRIES reported its financial results for the third quarter of FY2023. The company’s stock opened at $9.3 and closed at $9.2, up by 1.2% from the prior closing price of 9.0. The company’s revenue was driven primarily by strong growth in its generics business, offset by the impact of a weaker generic pricing environment and the impact of currency fluctuations.
TEVA PHARMACEUTICAL INDUSTRIES also reported successful progress in its cost cutting and efficiency initiatives, which resulted in a reduction in its operating expenses for the quarter. The company is confident that it will continue to deliver strong earnings in the future, as it continues to focus on cost efficiency and strategic partnerships with other pharmaceutical companies. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for TEVA. More…
| Total Revenues | Net Income | Net Margin |
| 15.27k | -2.21k | 4.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for TEVA. More…
| Operations | Investing | Financing |
| 1.16k | 835 | -2.05k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for TEVA. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 42.09k | 34.58k | 6.18 |
Key Ratios Snapshot
Some of the financial key ratios for TEVA are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -2.9% | -4.4% | -7.7% |
| FCF Margin | ROE | ROA |
| 4.0% | -10.6% | -1.8% |
Analysis
GoodWhale conducted an analysis of TEVA PHARMACEUTICAL INDUSTRIES’s wellbeing, and found that they had a high health score of 7/10 according to their cash flows and debt. We classified TEVA PHARMACEUTICAL INDUSTRIES as an “elephant” company, meaning that they had a wealth of assets after subtracting off liabilities. Our evaluation of TEVA PHARMACEUTICAL INDUSTRIES revealed that they are strong in profitability, but weak in asset, dividend, and growth. Given this information, investors who are interested in a company with a high health score and a wealth of assets could be interested in TEVA PHARMACEUTICAL INDUSTRIES. Investors who are looking for strong dividend and growth potential may want to look elsewhere. Ultimately, it is up to the individual investor to determine which type of company is best for their portfolio. More…
Summary
Teva Pharmaceutical Industries reported strong financial results for the third quarter of FY2023, ending September 30 2023, indicating increasing demand and profitability. Total revenues increased 7.1% YoY to USD 3850.0 million, with a 42.9% jump in net income to USD 80.0 million. The company’s strong financials underpin its long-term growth potential, making it an attractive investment for those seeking a comparatively lower volatility play in the pharmaceutical sector. Teva’s expansion strategies, innovative product pipeline, and cost-effective production capabilities all point to continued success in the future.
Related Posts
Recent Posts
